grupo panvel



HIGHLIGHTS

3Q22

Retail Gross

Revenue

R\$ 995M (+26.3%)

Group's Gross Revenue

R\$ 1,088M (+26.5%)

Retail Gross

Margin

30.5% (+0.9 p.p.)

Digital

16.1% of Sales

(+25.8% vs 3Q21)

Adjusted

EBITDA

R\$ 48.5M (+39.1%)

Margin of 4.5%

Expansion

+ 68 New Stores (LTM)

+ 14 new stores (3Q22)

Market

Share 📶



+ 0.9 p.p.

(vs 3Q21)


NPS



81

CONSISTENT GROWTH

Evolution - Gross Retail Revenue (2011-2021)




CAGR 3Q19/3Q22 15.7%

CAGR 9M19/9M22 15.6%





GROSS REVENUE: PANVEL GROWS 26.3% AND PRESENTS ANOTHER QUARTER OF GROWTH

ABOVE THE INDUSTRY AVERAGE



Average sales reaches
R\$ 605,000 per store/month 3Q22






MSSS AND SSS SHOW ROBUST GROWTH IN 3Q22, ABOVE INFLATION




PANVEL OPENS 14 STORES IN 3Q22 AND 68 STORES IN 12 MONTHS,

ANOTHER HISTORICAL RECORD



ANOTHER CONSECUTIVE QUARTER OF MARKET SHARE GAIN IN ALL STATES IN THE SOUTHERN **REGION**





Gain of 0.9 p.p. in Market Share




DIGITAL: THE HIGHEST MARKET PENETRATION, WITH THE FASTEST DELIVERY IN BRAZIL AND HEALTHY

MARGINS











Click and Collect 548 Stores



Service Level 97% (3Q22)



Deliveries 3Q22 +875,000



Delivery Stores 133



Mini CD/ **Darkstore** 9




Fast Delivery up to 1h

% Deliveries in 60 Minutes (2022)



SERVICES: CONSOLIDATED LEADERSHIP IN THE SOUTHERN REGION



Leadership

services in the Southern Region (3Q22): 15.1% of Markekt Share



Leader in vaccination in the Southern Region (3Q22): 53.5% de Market Share

Source: IQVIA

347

Clinic Stores (+50 rooms vs 3Q21) 86

Vaccine rooms (+14 rooms vs 3Q21)

PANVEL PRODUCTS FOLLOW AS BENCHMARK OF FARMA RETAIL

PRIVATE LABEL SALES GROWS

10.8% IN 3Q22 vs 3Q21

28.2% ex-masks

WITH SHARE OF

18.9% OF TOTAL **HB SALES**


LTM LAUNCHES REPRESENT 21.6% OF PANVEL PRODUCT SALES ON HB

- +1,000 active SKU's
- **Higher Gross Margin**
- Leader in 40% in categories from the chain

% Share of Private Label on Retais Sales



% Share of Private Label on HB Sales





PANVEL OFFERS THE BEST EXPERIENCE FOR THE CUSTOMER



Panvel

81



NPS Site

83



NPS App

86



NPS Alô



2022 (IBEVAR) MOST ADMIRED PHARMACY AWARD

NPS Loja



NPS Dark Stores

80



NPS Clinic

86



Reclame Aqui

8,6



E-bit





IN BRAZIL

App **Store**



Play **Store**

4,8



RANKING 2022

IBEVAR-FIA


NS Alô


95%



NS Sac

GROSS RETAIL MARGIN EXPANDS 0.9 P.P. AT 3Q22 VS 3Q21, REACHING 30.5% OF GROSS REVENUE






- ✓ Generics with growth of 51.6% vs. 3Q21;
- ✓ OTC with growth of 38.5% vs 3Q21;
- Balanced Sales Mix Offset The Lowest Participation of Services in 3Q22.




EXPENSE MANAGEMENT CONTINUES WITH A FOCUS ON PRODUCTIVITY

Selling Expenses



 Selling Expenses are still impacted by the expansion of stores, but remain in relation to previous quarters.

G&A Expenses



■ **G&A** grow 0.1 p.p. in 3Q22 vs. 3Q21, maintaining healthy level.

ADJUSTED EBITDA (GROUP): GROWTH OF 39.1% OVER THE SAME PERIOD IN 2021

- **✓** Strong Gross Revenue Growth
- ✓ Gross Margin Expansion in Retail and Wholesale
- ✓ Operational Leverage in Mature Store Expenses, offsetting expansion expenses.




RETAIL EBITDA GROWS 0.6 p.p. vs. 3Q21

(BRL million)




(% of Gross Revenue)




- **✓** Retail Gross Margin Expansion
- ✓ Strong performance of mature store base
- ✓ Expansion performing higher than expected

ADJUSTED NET PROFIT GROWS 16.3% COMPARED TO 3Q21 AND MAINTAINS CONSISTENCY


- √ Strong operating performance (EBITDA)
- ✓ Impact of Financial Expenses of 0.5 p.p. in 3Q22



(% of Gross Revenue)



CASH CYCLE PRESENTS 4 DAY IMPROVEMENT



Net Debt	3Q21	4Q21	1Q22	2Q22	3Q22
Short-Term Debt	57.3	56.0	60.5	88.2	97.9
Long-Term Debt	107,3	80.4	80.1	172.9	172.9
Gross Debt	164,6	136,4	139,6	261,2	270,7
(-) Cash and Cash Equivalents	205,5	209,7	95,9	127,0	164,3
Net Debt / Net Cash	(41,0)	(73,2)	43,7	134,2	106,5
Net Debt / EBITDA	n/a	n/a	0,27x	0,75x	0,55x

- Solid Capital Structure
- low leverage

STRATEGIC PILLARS
















INNOVATION & TECHNOLOGY


PEOPLE & CULTURE




STRATEGIC EXPANSION







Cities with Panvel stores +21 new cities 2019 - 09/2022






Focus on the Southern Region

Pop and Standard models

Countryside


STRATEGIC EXPANSION – AVERAGE SALE PER STORE/MONTH AND RETAIL EBITDA

Average Sale 12th month per Vintage vs Average Sale of Chain




in Thousands of R\$	2018	2019	2020	2021
Average Sales Chain	449	477	474	512
Average Sale 12th month per Vintage	421	415	450	533
Average Sale 12th month per Vintage (Curve)	94%	87%	95%	104%

Retail EBITDA per Vintage




STRATEGIC EXPANSION – ROIC Return of Investment (ROIC)




CRM & CUSTOMERS – CUSTOMERS BASE INCREASES 24.8% AND FREQUENCY INCREASES 5% IN 3Q22

Bem Panyel Customers Evolution (in Millions)






Active Customers Evolution (in Millions)




3Q21 4Q21 1Q22 2Q22 3Q22

Bem Panvel - Population in the **Southern Region** (IBGE 2021)




■ Souther Region ■ Bem Panvel

Field Customers Evolution







Customer Digitalization Omni Customers Evolution Semester attendance (Omni Customers) +0.7 p.p. 17 11 10.5% 10.4% 10.2% 10.1% 9.5% **Field** General Averege **Customers 2Q22 3Q22** 3Q21 4Q21 **1Q22**

Highlights and Conclusions

SALES AND MARKET SHARE WITH ROBUST GROWTH

- Balanced inventories and low stockouts;
- Special focus on medicines, bringing in new customers and greater recurrence in stores;
- Growth of mature stores above inflation;
- Accelerated ramp up of new stores;
- Active customer base and omni customer base with strong growth.

■ HEALTHY GROSS MARGIN

 Efficient product mix management, with emphasis on Generics and the resumption of Hygiene and Beauty categories and Panvel Products.

EBITDA MARGIN EVOLVING EACH YEAR

- Strong operational leverage from mature stores;
- Store expansion will have a progressively less impact in the coming years;
- Scale gains in Logistics.

☐ ALL STRATEGIC PILLARS ARE CONTRIBUTING TO THE GROWTH OF SALES AND RESULTS

grupo panvel Q&A

Investor Relations

Antônio Carlos Tocchetto Napp CFO and IRO

Ismael Rohrig IR Specialist

Pedro Bernardes IR Assistent

Pedro Gazzana IR Intern

Phone: +55 51 3481.9999 / 3481.9588 relinvest@grupopanvel.com.br grupopanvel.com.br/ri











management's expectations about the future of the business. These expectations depend substantially on market conditions, legislation, the performance of the Brazilian economy, the sector and international markets and, therefore, subject to change without notice.

